Skip to main content
Quest Diagnostics

Diagnostic Utility of Ki-67 Index on Cell Block Material for Grading Medullary Thyroid Carcinoma

Diagnostic Utility of Ki-67 Index on Cell Block Material for Grading Medullary Thyroid Carcinoma

Authors: Hou T, Mesa H, Puello B, Molden B

Citation: Diagn Cytopathol. 2026 Feb 16. doi: 10.1002/dc.70102. Online ahead of print.

Specialties: Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Publication
Free T4 Age-Specific Reference Intervals from Birth to the 10th Decade of Life Using Direct Dialysis
Publication
Validation of a Compact and Self-Contained Pyrosequencing Platform for Clinical Screening of RAS Mutations in Thyroid Cancers

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.